Difference between revisions of "Loricrin (TG1)"
| Line 29: | Line 29: | ||
|- | |- | ||
| Substrate sequence | | Substrate sequence | ||
| − | | | + | | SY''QKKQ''PTP''Q''PPV |
| + | |||
| + | SGGSV''K''YSGGG | ||
FSG''Q''AV''Q''CQSY | FSG''Q''AV''Q''CQSY | ||
| Line 37: | Line 39: | ||
AP''Q''PSYGGG | AP''Q''PSYGGG | ||
| − | CH''Q''T''QQKQ'' | + | CH''Q''T''QQKQ''APTWPS''K'' |
|- | |- | ||
| Structure | | Structure | ||
Revision as of 08:58, 24 July 2007
| Template:Infobox header| Loricrin (TG1) | |
|---|---|
| Loricrin (TG1) | |
| Substrate peptide name | Loricrin (TG1) |
| Synonyms | - |
| Determination type | In situ |
| Source | Homo sapiens |
| Subcellular localization | Cornified envelope |
| Swissprot ID | P23490 |
| Reactive glutamines | Q3, Q6, Q10, Q153, Q156, Q215, Q216, Q219, Q225, Q303, Q305, Q306, Q308 |
| Reactive lysines | K4, K5, K88, K307, K315 |
| Substrate sequence | SYQKKQPTPQPPV
SGGSVKYSGGG FSGQAVQCQSY YVSSQQVTQTSCA APQPSYGGG CHQTQQKQAPTWPSK |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:2007607 |
| Notes | |
| Template:Infobox header | | |
.png){kind=link}